Influence of renal replacement modalities on amikacin population pharmacokinetics in critically ill patients on continuous renal replacement therapy

Antimicrobial Agents and Chemotherapy

Volumn 60, Issue 8, 2016, Pages 4901-4909

  Roger, Claire ^a,b   Wallis, Steven C ^b   Muller, Laurent ^a   Saissi, Gilbert ^a   Lipman, Jeffrey ^b,c   Lefrant, Jean Yves ^a   Roberts, Jason A ^b,c  

^a NÎMES UNIVERSITY HOSPITAL   (France)

^b UNIVERSITY OF QUEENSLAND   (Australia)

^c ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; CREATININE; HYPERTENSIVE FACTOR; SERUM ALBUMIN; ANTIINFECTIVE AGENT;

AGED; ARTICLE; BURN PATIENT; CLINICAL ARTICLE; CONTINUOUS HEMODIAFILTRATION; CONTINUOUS HEMOFILTRATION; CONTINUOUS RENAL REPLACEMENT THERAPY; CREATININE BLOOD LEVEL; CRITICALLY ILL PATIENT; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG MONITORING; FEMALE; HUMAN; MALE; MINIMUM INHIBITORY CONCENTRATION; MONTE CARLO METHOD; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROSTHESIS INFECTION; CONTROLLED STUDY; CRITICAL ILLNESS; DRUG EFFECTS; HEMODIAFILTRATION; HEMOFILTRATION; KIDNEY; METABOLIC CLEARANCE RATE; METABOLISM; PROCEDURES; RANDOMIZED CONTROLLED TRIAL; RENAL REPLACEMENT THERAPY;

AGED; AMIKACIN; ANTI-BACTERIAL AGENTS; CRITICAL ILLNESS; FEMALE; HEMODIAFILTRATION; HEMOFILTRATION; HUMANS; KIDNEY; MALE; METABOLIC CLEARANCE RATE; MONTE CARLO METHOD; RENAL REPLACEMENT THERAPY;

EID: 84979574407     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00828-16     Document Type: Article

References (34)

1. Moore RD, Lietman PS, Smith CR. 1987. Clinical response to aminoglycoside therapy: importance of the ratio of Cmax concentration to minimal inhibitory concentration. J Infect Dis 155:93-99. http://dx.doi.org/10.1093/infdis/155.1.93.
2. Moore RD, Smith CR, Lietman PS. 1984. Association of aminoglycoside plasma levels with therapeutic outcome in gram-negative pneumonia. Am J Med 77:657-662. http://dx.doi.org/10.1016/0002-9343(84)90358-9.
3. Craig WA, Redington J, Ebert SC. 1991. Pharmacodynamics of amikacin in vitro and in mouse thigh and lung infections. J Antimicrob Chemother 27(Suppl C):C29-C40.
4. Rybak MJ, Abate BJ, Kang SL, Ruffing MJ, Lerner SA, Drusano GL. 1999. Prospective evaluation of the effect of an aminoglycoside dosing regimen on rates of observed nephrotoxicity and ototoxicity. Antimicrob Agents Chemother 43:1549-1555.
5. Zelenitsky SA, Harding GK, Sun S, Ubhi K, Ariano RE. 2003. Treatment and outcome of Pseudomonas aeruginosa bacteraemia: an antibiotic pharmacodynamic analysis. J Antimicrob Chemother 52:668-674. http://dx.doi.org/10.1093/jac/dkg403.
6. Roberts JA, Lipman J. 2009. Pharmacokinetic issues for antibiotics in the critically ill patient. Crit Care Med 37:840-851. http://dx.doi.org/10.1097/CCM.0b013e3181961bff.
7. Pea F, Viale P, Furlanut M. 2005. Antimicrobial therapy in critically ill patients: a review of pathophysiological conditions responsible for altered disposition and pharmacokinetic variability. Clin Pharmacokinet 44:1009-034. http://dx.doi.org/10.2165/00003088-200544100-00002.
8. Uchino S, Kellum JA, Bellomo R, Doig GS, Morimatsu H, Morgera S, Schetz M, Tan I, Bouman C, Macedo E, Gibney N, Tolwani A, Ronco C, Beginning and Ending Supportive Therapy for the Kidney (BEST Kidney) Investigators. 2005. Acute renal failure in critically ill patients: a multinational, multicenter study. JAMA 294:813-818. http://dx.doi.org/10.1001/jama.294.7.813.
9. Schneider AG, Bellomo R, Bagshaw SM, Glassford NJ, Lo S, Jun M, Cass A, Gallagher M. 2013. Choice of renal replacement therapy modality and dialysis dependence after acute kidney injury: a systematic review and meta-analysis. Intensive Care Med 39:987-997. http://dx.doi.org/10.1007/s00134-013-2864-5.
10. Akers KS, Cota JM, Frei CR, Chung KK, Mende K, Murray CK. 2011. Once-daily amikacin dosing in burn patients treated with continuous venovenous hemofiltration. Antimicrob Agents Chemother 55:4639-4642. http://dx.doi.org/10.1128/AAC.00374-11.
11. Taccone FS, de Backer D, Laterre PF, Spapen H, Dugernier T, Delattre I, Wallemacq P, Vincent JL, Jacobs F. 2011. Pharmacokinetics of a loading dose of amikacin in septic patients undergoing continuous renal replacement therapy. Int J Antimicrob Agents 37:531-535. http://dx.doi.org/10.1016/j.ijantimicag.2011.01.026.
12. D'Arcy DM, Casey E, Gowing CM, Donnelly MB, Corrigan OI. 2012. An open prospective study of amikacin pharmacokinetics in critically ill patients during treatment with continuous venovenous hemodiafiltration. BMC Pharmacol Toxicol 13:14. http://dx.doi.org/10.1186/2050-6511-13-14.
13. Robert R, Rochard E, Malin F, Bouquet S. 1991. Amikacin pharmacokinetics during continuous veno-venous hemofiltration. Crit Care Med 19:588-589. http://dx.doi.org/10.1097/00003246-199104000-00029.
14. Lam SW, Bauer SR. 2013. Amikacin pharmacokinetics during continuous veno-venous hemodialysis. Infect Dis Ther 2:217-226. http://dx.doi.org/10.1007/s40121-013-0012-8.
15. Kinowski JM, de la Coussaye JE, Bressolle F, Fabre D, Saissi G, Bouvet O, Galtier M, Eledjam JJ. 1993. Multiple-dose pharmacokinetics of amikacin and ceftazidime in critically ill patients with septic multiple-organ failure during intermittent hemofiltration. Antimicrob Agents Chemother 37:464-473. http://dx.doi.org/10.1128/AAC.37.3.464.
16. Pea F, Viale P, Pavan F, Furlanut M. 2007. Pharmacokinetic considerations for antimicrobial therapy in patients receiving renal replacement therapy. Clin Pharmacokinet 46:997-1038. http://dx.doi.org/10.2165/00003088-200746120-00003.
17. Joannidis M, Oudemans-van Straaten HM. 2007. Clinical review: patency of the circuit in continuous renal replacement therapy. Crit Care 11:218. http://dx.doi.org/10.1186/cc5937.
18. Le Gall JR, Lemeshow S, Saulnier F. 1993. A new Simplified Acute Physiology Score (SAPS II) based on a European/North American multicenter study. JAMA 270:2957-2963.
19. Vincent JL, de Mendonca A, Cantraine F, Moreno R, Takala J, Suter PM, Sprung CL, Colardyn F, Blecher S. 1998. Use of the SOFA score to assess the incidence of organ dysfunction/failure in intensive care units: results of a multicenter, prospective study. Working Group on "Sepsis-Related Problems" of the European Society of Intensive Care Medicine. Crit Care Med 26:1793-1800.
20. Tatarinova T, Neely M, Bartroff J, van Guilder M, Yamada W, Bayard D, Jelliffe R, Leary R, Chubatiuk A, Schumitzky A. 2013. Two general methods for population pharmacokinetic modeling: non-parametric adaptive grid and non-parametric Bayesian. J Pharmacokinet Pharmacodyn 40:189-199. http://dx.doi.org/10.1007/s10928-013-9302-8.
21. Neely MN, van Guilder MG, Yamada WM, Schumitzky A, Jelliffe RW. 2012. Accurate detection of outliers and subpopulations with Pmetrics, a nonparametric and parametric pharmacometric modeling and simulation package for R. Ther Drug Monit 34:467-476. http://dx.doi.org/10.1097/FTD.0b013e31825c4ba6.
22. ANSM. Bon usage des aminosides administrés par voie injectable: gentamycine, tobramycine, netimicine, amikacine - mise au point. ANSM, Paris, France. http://ansm.sante.fr/Mediatheque/Publications/Recommandations-Medicaments.
23. Drusano GL, Ambrose PG, Bhavnani SM, Bertino JS, Nafziger AN, Louie A. 2007. Back to the future: using aminoglycosides again and how to dose them optimally. Clin Infect Dis 45:753-760. http://dx.doi.org/10.1086/520991.
24. Taccone FS, Laterre PF, Spapen H, Dugernier T, Delattre I, Layeux B, De Backer D, Wittebole X, Wallemacq P, Vincent JL, Jacobs F. 2010. Revisiting the loading dose of amikacin for patients with severe sepsis and septic shock. Crit Care 14:R53. http://dx.doi.org/10.1186/cc8945.
25. Galvez R, Luengo C, Cornejo R, Kosche J, Romero C, Tobar E, Illanes V, Llanos O, Castro J. 2011. Higher than recommended amikacin loading doses achieve pharmacokinetic targets without associated toxicity. Int J Antimicrob Agents 38:146-151. http://dx.doi.org/10.1016/j.ijantimicag.2011.03.022.
26. Roger C, Nucci B, Molinari N, Bastide S, Saissi G, Pradel G, Barbar S, Aubert C, Lloret S, Elotmani L, Polge A, Lefrant JY, Roberts JA, Muller L. 2015. Standard dosing of amikacin and gentamicin in critically ill patients results in variable and subtherapeutic concentrations. Int J Antimicrob Agents 46:21-27. http://dx.doi.org/10.1016/j.ijantimicag.2015.02.009.
27. de Montmollin E, Bouadma L, Gault N, Mourvillier B, Mariotte E, Chemam S, Massias L, Papy E, Tubach F, Wolff M, Sonneville R. 2014. Predictors of insufficient amikacin Cmax concentration in critically ill patients receiving a 25 mg/kg total body weight regimen. Intensive Care Med 40:998-1005. http://dx.doi.org/10.1007/s00134-014-3276-x.
28. Roger C, Nucci B, Louart B, Friggeri A, Knani H, Evrard A, Lavigne JP, Allaouchiche B, Lefrant JY, Roberts JA, Muller L. 2016. Impact of 30 mg/kg amikacin and 8 mg/kg gentamicin on serum concentrations in critically ill patients with severe sepsis. J Antimicrob Chemother 71:208-212. http://dx.doi.org/10.1093/jac/dkv291.
29. Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group. 2012. KDIGO clinical practice guideline for acute kidney injury. Chapter 5.8: dose of renal replacement therapy in AKI. Kidney Int 2(Suppl):113-115.
30. Heintz BH, Matzke GR, Dager WE. 2009. Antimicrobial dosing concepts and recommendations for critically ill adult patients receiving continuous renal replacement therapy or intermittent hemodialysis. Pharmacotherapy 29:562-577. http://dx.doi.org/10.1592/phco.29.5.562.
31. Trotman RL, Williamson JC, Shoemaker DM, Salzer WL. 2005. Antibiotic dosing in critically ill adult patients receiving continuous renal replacement therapy. Clin Infect Dis 41:1159-1166. http://dx.doi.org/10.1086/444500.
32. Choi G, Gomersall CD, Tian Q, Joynt GM, Freebairn R, Lipman J. 2009. Principles of antibacterial dosing in continuous renal replacement therapy. Crit Care Med 37:2268-2282. http://dx.doi.org/10.1097/CCM.0b013e3181aab3d0.
33. Brasseur A, Hites M, Roisin S, Cotton F, Vincent JL, De Backer D, Jacobs F, Taccone FS. 2016. A high-dose aminoglycoside regimen combined with renal replacement therapy for the treatment of MDR pathogens: a proof-of-concept study. J Antimicrob Chemother 71:1386-1394. http://dx.doi.org/10.1093/jac/dkv491.
34. Roberts JA, Udy AA, Jarrett P, Wallis SC, Hope WW, Sharma R, Kirkpatrick CM, Kruger PS, Roberts MS, Lipman J. 2015. Plasma and target-site subcutaneous tissue population pharmacokinetics and dosing simulations of cefazolin in post-trauma critically ill patients. J Antimicrob Chemother 70:1495-1502. http://dx.doi.org/10.1093/jac/dku564.